3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Colorectal Neoplasms
3
Breast Neoplasms
3
Stomatitis
2
Neoplasms
2
Mucositis
2
Vulvodynia
1
Urologic Neoplasms
1
Urologic Diseases
1
Urolithiasis
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Skin Neoplasms
1
Pain, Postoperative
1
Pain
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Multiple Endocrine Neoplasia Type 1
1
Mobility Limitation
1
MRSA Colonization
1
Lymphoma
1
Leukemia
1
Ilues
1
Hydronephrosis
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Dyspareunia
1
Disease
1
Interventions
Gemcitabine
74
Capecitabine
60
Paclitaxel
59
Fluorouracil
58
Oxaliplatin
57
Bevacizumab
51
Docetaxel
50
Leucovorin
48
Nivolumab
40
Cisplatin
40
Irinotecan
39
Carboplatin
37
Cetuximab
33
pembrolizumab
32
Radiosurgery
32
Trastuzumab
30
Radiotherapy
27
Everolimus
24
Sorafenib
23
Pemetrexed
20
Doxorubicin
20
Albumin-Bound Paclitaxel
20
Ipilimumab
19
Cyclophosphamide
19
Panitumumab
18
Zoledronic Acid
17
Lapatinib
17
Erlotinib Hydrochloride
17
Prednisone
16
pazopanib
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neoplasm Metastasis
×
Water
×
Clear all
NCT04799249
2024-08-01
PRESERVE 2
G1 Therapeutics, Inc.
Phase 3
Completed
194 enrolled